Loading patent…
AssigneeYale University
InventorMarkus Müschen
Estimating the term…
The present invention relates of treating a lymphocyte associated disease or condition, the method comprising administering to a subject in need thereof an effective amount of an agonist or activator of a β-catenin:Ikaros zinc finger (IKZF) protein complex. The present invention relates also to methods of eradicating pathogenic lymphocyte populations or enhancing adoptive cellular therapy (ACT) (e.g., via preconditioning) in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agonist or activator of a β-catenin:IKZF protein complex. The present invention also relates to methods of treating a lymphopenic associated disease or condition or enhancing ACT, the method comprising administering to a subject in need thereof an effective amount of an agent that inhibits the expression or function of β-catenin or a β-catenin:IKZF protein complex.
A method of treating a lymphocyte associated disease or condition, the method comprising administering to a subject in need thereof an effective amount of an agonist or activator of a β-catenin:Ikaros zinc finger (IKZF) protein complex.
A method of eradicating pathogenic lymphocyte populations, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agonist or activator of a β-catenin:Ikaros zinc finger (IKZF) protein complex.
A method of enhancing adoptive cellular therapy (ACT) in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agonist or activator of a β-catenin:Ikaros zinc finger (IKZF) protein complex.
A method of treating a lymphopenic associated disease or condition, the method comprising administering to a subject in need thereof an effective amount of an agent that inhibits the expression or function of β-catenin or a β-catenin:Ikaros zinc finger (IKZF) protein complex.
A method of enhancing adoptive cellular therapy (ACT) in a subject, the method comprising administering to a subject in need thereof or an ACT preparation a therapeutically effective amount of an agent that inhibits the expression or function of β-catenin or a β-catenin:Ikaros zinc finger (IKZF) protein complex.
Dependencies are inferred from the claim text.